141 related articles for article (PubMed ID: 3650100)
1. Neutralizing antibodies and the course of HIV-induced disease.
Wendler I; Bienzle U; Hunsmann G
AIDS Res Hum Retroviruses; 1987; 3(2):157-63. PubMed ID: 3650100
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.
Ho DD; Sarngadharan MG; Hirsch MS; Schooley RT; Rota TR; Kennedy RC; Chanh TC; Sato VL
J Virol; 1987 Jun; 61(6):2024-8. PubMed ID: 2437327
[TBL] [Abstract][Full Text] [Related]
3. Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases.
Robert-Guroff M; Oleske JM; Connor EM; Epstein LG; Minnefor AB; Gallo RC
Pediatr Res; 1987 Jun; 21(6):547-50. PubMed ID: 3474582
[TBL] [Abstract][Full Text] [Related]
4. HTLV-III neutralizing antibody development in transfusion-dependent seropositive patients with beta-thalassemia.
Robert-Guroff M; Giardina PJ; Robey WG; Jennings AM; Naugle CJ; Akbar AN; Grady RW; Hilgartner MW
J Immunol; 1987 Jun; 138(11):3731-6. PubMed ID: 3495568
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.
Ranki A; Weiss SH; Valle SL; Antonen J; Krohn KJ
Clin Exp Immunol; 1987 Aug; 69(2):231-9. PubMed ID: 3652531
[TBL] [Abstract][Full Text] [Related]
6. Characterization of serum neutralization response to the human immunodeficiency virus (HIV).
Groopman JE; Benz PM; Ferriani R; Mayer K; Allan JD; Weymouth LA
AIDS Res Hum Retroviruses; 1987; 3(1):71-85. PubMed ID: 2441727
[TBL] [Abstract][Full Text] [Related]
7. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.
Lyerly HK; Reed DL; Matthews TJ; Langlois AJ; Ahearne PA; Petteway SR; Weinhold KJ
AIDS Res Hum Retroviruses; 1987; 3(4):409-22. PubMed ID: 2833917
[TBL] [Abstract][Full Text] [Related]
8. Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses.
Nara PL; Robey WG; Arthur LO; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC; Fischinger PJ
J Virol; 1987 Oct; 61(10):3173-80. PubMed ID: 2442411
[TBL] [Abstract][Full Text] [Related]
9. Variable and conserved neutralization antigens of human immunodeficiency virus.
Weiss RA; Clapham PR; Weber JN; Dalgleish AG; Lasky LA; Berman PW
Nature; 1986 Dec 11-17; 324(6097):572-5. PubMed ID: 2431324
[TBL] [Abstract][Full Text] [Related]
10. Detection of HIV envelope specific antibodies by immunoelectron microscopy and correlation with antibody titer and virus neutralizing activity.
Hausmann EH; Gelderblom HR; Clapham PR; Pauli G; Weiss RA
J Virol Methods; 1987 May; 16(1-2):125-37. PubMed ID: 3038935
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
[TBL] [Abstract][Full Text] [Related]
12. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages.
Ljunggren K; Böttiger B; Biberfeld G; Karlson A; Fenyö EM; Jondal M
J Immunol; 1987 Oct; 139(7):2263-7. PubMed ID: 3498755
[TBL] [Abstract][Full Text] [Related]
13. Human retrovirus infection and immunodeficiencies. Detection and significance of virus-neutralizing antibodies.
Faulkner-Valle GP; De Rossi A; Dalla Gassa O; Francavilla E; Amadori A; Chieco-Bianchi L
Antibiot Chemother (1971); 1987; 38():159-66. PubMed ID: 3662468
[No Abstract] [Full Text] [Related]
14. Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status.
Franchini G; Robert-Guroff M; Aldovini A; Kan NC; Wong-Staal F
Blood; 1987 Feb; 69(2):437-41. PubMed ID: 3467797
[TBL] [Abstract][Full Text] [Related]
15. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I.
Böttiger B; Ljunggren K; Karlsson A; Krohn K; Fenyö EM; Jondal M; Biberfeld G
Clin Exp Immunol; 1988 Sep; 73(3):339-42. PubMed ID: 3208445
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of antibodies to HIV nuclear proteins in patients with the lymphadenopathy syndrome].
Schulte C; Meurer M; Fröschl M
Hautarzt; 1988 Jan; 39(1):45-8. PubMed ID: 3162727
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study.
Sei Y; Tsang PH; Roboz JP; Sarin PS; Wallace JI; Bekesi JG
J Clin Immunol; 1988 Nov; 8(6):464-72. PubMed ID: 3146584
[TBL] [Abstract][Full Text] [Related]
19. Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection.
Goudsmit J; Lange JM; Paul DA; Dawson GJ
J Infect Dis; 1987 Mar; 155(3):558-60. PubMed ID: 3468176
[No Abstract] [Full Text] [Related]
20. Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens.
Kenealy W; Reed D; Cybulski R; Tribe D; Taylor P; Stevens C; Matthews T; Petteway S
AIDS Res Hum Retroviruses; 1987; 3(1):95-105. PubMed ID: 3304356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
